Publications
Detailed Information
Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, B. -S. | - |
dc.contributor.author | Kim, D. -W. | - |
dc.contributor.author | Im, S. -A. | - |
dc.contributor.author | Kim, C. W. | - |
dc.contributor.author | Kim, T. -Y. | - |
dc.contributor.author | Yoon, S. -S. | - |
dc.contributor.author | Heo, D. S. | - |
dc.contributor.author | Bang, Y. -J. | - |
dc.contributor.author | Park, S. | - |
dc.contributor.author | Kim, B. K. | - |
dc.contributor.author | Kim, N. K. | - |
dc.date.accessioned | 2012-05-24T00:42:10Z | - |
dc.date.available | 2012-05-24T00:42:10Z | - |
dc.date.created | 2020-02-19 | - |
dc.date.created | 2020-02-19 | - |
dc.date.created | 2020-02-19 | - |
dc.date.issued | 2009-01 | - |
dc.identifier.citation | Annals of Oncology, Vol.20 No.1, pp.121-128 | - |
dc.identifier.issn | 0923-7534 | - |
dc.identifier.other | 91879 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76366 | - |
dc.description.abstract | Background: Many patients with extranodal natural killer/T-cell lymphoma (NTCL) fail to the front-line therapy and need an effective second-line chemotherapy. Patients and methods: This was single-institutional, phase II study. The primary end point was response rate and secondary end points were toxicity, time to treatment failure (TTF), and overall survival (OS). Patients with relapsed or refractory NTCL were eligible. They received the chemotherapy consisting of ifosfamide, methotrexate, etoposide, and prednisolone and it was repeated every 3 weeks. Results: Thirty-two patients were enrolled and 15 patients had achieved partial remission (PR) or complete remission (CR) after the front-line chemotherapy. The International Prognostic Index scores were 0-1 in thirteen, 2 in five, 3 in five, and 4-5 in nine patients. Twelve and two patients achieved CR and PR, respectively. Median OS and TTF of all patients were 8.2 and 3.7 months, respectively. Non-hematologic toxic effects were well tolerated, but grade 3/4 leukopenia occurred in 11.7% of all cycles. Four patients developed febrile neutropenia and one patient died due to pneumonia. Conclusions: This chemotherapy regimen was moderately effective for relapsed/refractory extranodal NTCL, nasal type. Toxic effects were moderate, but caution should be exercised to prevent severe infection. | - |
dc.language | 영어 | - |
dc.language.iso | en | ko_KR |
dc.publisher | Oxford University Press | - |
dc.title | Effective second-line chemotherapy for extranodal NK/T-cell lymphoma consisting of etoposide, ifosfamide, methotrexate, and prednisolone | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 임석아 | - |
dc.identifier.doi | 10.1093/annonc/mdn551 | - |
dc.citation.journaltitle | Annals of Oncology | - |
dc.description.citedreference | Lee KW, 2006, LEUKEMIA LYMPHOMA, V47, P1274, DOI 10.1080/10428190600562823 | - |
dc.description.citedreference | Kim HJ, 2006, BONE MARROW TRANSPL, V37, P819, DOI 10.1038/sj.bmt.1705349 | - |
dc.description.citedreference | Suzuki R, 2006, BONE MARROW TRANSPL, V37, P425, DOI 10.1038/sj.bmt.1705244 | - |
dc.description.citedreference | Kim TM, 2005, BLOOD, V106, P3785 | - |
dc.description.citedreference | You JY, 2004, ANN ONCOL, V15, P618, DOI 10.1093/annonc/mdh143 | - |
dc.description.citedreference | Li CC, 2004, CANCER, V100, P366, DOI 10.1002/cncr.11908 | - |
dc.description.citedreference | Chim CS, 2004, BLOOD, V103, P216, DOI 10.1182/blood-2003-05-1401 | - |
dc.description.citedreference | Kim BS, 2003, ACTA ONCOL, V42, P779, DOI 10.1080/02841860310010682 | - |
dc.description.citedreference | Yong WB, 2003, INT J HEMATOL, V78, P163 | - |
dc.description.citedreference | Matsumoto Y, 2003, LEUKEMIA LYMPHOMA, V44, P879, DOI 10.1080/1042819031000067873 | - |
dc.description.citedreference | Nagafuji K, 2001, INT J HEMATOL, V74, P447 | - |
dc.description.citedreference | Shikama N, 2001, INT J RADIAT ONCOL, V51, P1228 | - |
dc.description.citedreference | Ribrag V, 2001, LEUKEMIA, V15, P1123 | - |
dc.description.citedreference | Kim WS, 2001, ANN ONCOL, V12, P349 | - |
dc.description.citedreference | YAMAGUCHI M, 2001, J CLIN EXP HEMATOPAT, V41, P93 | - |
dc.description.citedreference | Rodriguez J, 2000, LEUKEMIA LYMPHOMA, V39, P139 | - |
dc.description.citedreference | Kim GE, 2000, J CLIN ONCOL, V18, P54 | - |
dc.description.citedreference | Ko YH, 1998, CANCER, V83, P806 | - |
dc.description.citedreference | Li YX, 1998, CANCER, V83, P449 | - |
dc.description.citedreference | Cheung MMC, 1998, J CLIN ONCOL, V16, P70 | - |
dc.description.citedreference | Logsdon MD, 1997, CANCER, V80, P477 | - |
dc.description.citedreference | Shikama N, 1997, RADIOLOGY, V204, P467 | - |
dc.description.citedreference | Kwong YL, 1997, BRIT J HAEMATOL, V97, P821 | - |
dc.description.citedreference | CHAN JKC, 1997, BLOOD, V9, P4501 | - |
dc.description.citedreference | Jaffe ES, 1996, AM J SURG PATHOL, V20, P103 | - |
dc.description.citedreference | Chen HHW, 1996, RADIOTHER ONCOL, V38, P1 | - |
dc.description.citedreference | LIANG R, 1995, J CLIN ONCOL, V13, P666 | - |
dc.description.citedreference | CHAN JKC, 1994, AM J SURG PATHOL, V18, P938 | - |
dc.description.citedreference | VELASQUEZ WS, 1994, J CLIN ONCOL, V12, P1169 | - |
dc.description.citedreference | ARBER DA, 1993, AM J SURG PATHOL, V17, P392 | - |
dc.description.citedreference | SOBREVILLACALVO P, 1993, ACTA ONCOL, V32, P69 | - |
dc.description.citedreference | SMALLEY SR, 1988, INT J RADIAT ONCOL, V15, P599 | - |
dc.description.citedreference | VELASQUEZ WS, 1988, BLOOD, V71, P117 | - |
dc.description.citedreference | CABANILLAS F, 1982, BLOOD, V60, P693 | - |
dc.description.tc | 9 | - |
dc.identifier.wosid | 000262718000018 | - |
dc.identifier.scopusid | 2-s2.0-58949083841 | - |
dc.citation.endpage | 128 | - |
dc.citation.number | 1 | - |
dc.citation.startpage | 121 | - |
dc.citation.volume | 20 | - |
dc.identifier.sci | 000262718000018 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, D. -W. | - |
dc.contributor.affiliatedAuthor | Im, S. -A. | - |
dc.contributor.affiliatedAuthor | Kim, C. W. | - |
dc.contributor.affiliatedAuthor | Kim, T. -Y. | - |
dc.contributor.affiliatedAuthor | Yoon, S. -S. | - |
dc.contributor.affiliatedAuthor | Heo, D. S. | - |
dc.contributor.affiliatedAuthor | Bang, Y. -J. | - |
dc.contributor.affiliatedAuthor | Kim, B. K. | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | NATURAL KILLER/T-CELL | - |
dc.subject.keywordPlus | NON-HODGKINS-LYMPHOMA | - |
dc.subject.keywordPlus | INTERNATIONAL PROGNOSTIC INDEX | - |
dc.subject.keywordPlus | UPPER AERODIGESTIVE TRACT | - |
dc.subject.keywordPlus | NASAL CAVITY | - |
dc.subject.keywordPlus | RADIATION-THERAPY | - |
dc.subject.keywordPlus | L-ASPARAGINASE | - |
dc.subject.keywordPlus | CLINICOPATHOLOGICAL FEATURES | - |
dc.subject.keywordPlus | POLYMORPHIC RETICULOSIS | - |
dc.subject.keywordPlus | ANGIOCENTRIC LYMPHOMA | - |
dc.subject.keywordAuthor | NK/T-cell lymphoma | - |
dc.subject.keywordAuthor | Salvage chemotherapy | - |
dc.subject.keywordAuthor | Second-line chemotherapy | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.